ET-D5: Oral chemotherapy
Dr Aurélie Juhem is observing cancer cells incubated with ET-D5 using fluorescence microscopy
Dr Aurélie JUHEM met Dr Andrei Popov in 2005 to start her PhD training in his research team. They develop an innovative screening strategy to identify new anti-proliferative drugs targeting cell divison from a chemical library provided by the Institut Curie. They identified further new bioactive chemical entities including an ET-D5 structural analogue. Graduated in 2008 from Joseph Fourier University (Grenoble), she continued ET-D5 research program as a postdoctoral researcher with Dr Popov. This work was patented in 2010 and Ecrins therapeutics was founded to develop ET-D5 under preclinical studies.
Since 2010, Dr Aurelie Juhem is the R&D Director of Ecrins Therapeutics.